November 10, 2024 Wall Street Soars: Trump’s Victory Ignites Market Surge
November 2, 2024 Tech Titans’ Mixed Results Stall Wall Street Bull Run
October 28, 2024 Recent Oil Slides In Global Markets, Japan In Flux
Tesla’s Valuation: Unsupported By Fundamentals Or Future Growth
Tesla Stock Doesn’t Deserve This Rally
Nvidia: Q3 Earnings Could Ignite $200 Rally
Tesla: When Fundamentals Don’t Matter (Rating Downgrade)
Amazon Q3: Stop Buying The Stock For Now Because It’s Overvalued
October 22, 2024 A Comprehensive Guide to RoadRunner Auto Transport Services
October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
Magenta Therapeutics (MGTA) stock forecast for 2024
Updated: November 13, 2024 (08:37)
Sector: HealthcareThe share price of Magenta Therapeutics, Inc. (MGTA) now
50/200 Day Moving Average: $ / $
This figure corresponds to the Average Price over the previous 50/200 days. For Magenta Therapeutics stocks, the 50-day moving average is the support level today.
For Magenta Therapeutics stocks, the 200-day moving average is the support level today.
Are you interested in Magenta Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Magenta Therapeutics stock price in 2024. How much will one Magenta Therapeutics share be worth in 2024? Is it worth taking profit / loss on MGTA stock now or waiting? What are analysts' forecasts for Magenta Therapeutics stock?
We forecast Magenta Therapeutics stock performance using neural networks based on historical data on MGTA stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.
Magenta Therapeutics, Inc. stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Magenta Therapeutics analysts is $. Today 200 Day Moving Average is the support level ( $). 50 Day Moving Average is the support level ( $).
Historical and forecast chart of Magenta Therapeutics, Inc. stock
The chart below shows the historical price of Magenta Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the MGTA stock price can be found in the table below.
Magenta Therapeutics, Inc. is a clinical stage biotechnology company that develops new drugs for bone marrow transplantation. It offers a platform that focuses on critical areas of transplantation. The company was founded by David Scudden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, Massachusetts.
Magenta Therapeutics (MGTA) Forecast for 2024
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Dec | 0.76 | 0.68 | 0.78 | 13.30 % |
Magenta Therapeutics information and performance
N/A
Market capitalization of the Magenta Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of MGTA shares in the company outstanding by the market price of one share.
EBITDA of Magenta Therapeutics is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Magenta Therapeutics price target for 2024 by month
Target values for the price of one Magenta Therapeutics share for Dec 2024.
In Dec, the Positive dynamics for Magenta Therapeutics, Inc. shares will prevail with possible monthly volatility of 13.296% volatility is expected.
Pessimistic target level: 0.68
Optimistic target level: 0.78
Related stocks from Healthcare sector